AACR 2022

SGN-ALPV | Preclinical Models | Abstract #1766

SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models

SGN-B7H4V | ICD | Abstract #1281

SGN-B7H4V shows immunomodulatory activity through induction of immunogenic cell death

Enfortumab Vedotin | Preclinical Models | Abstract #5475

Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer